What is GNLX's current stock price?

GNLX (Genelux Corporation) is currently trading at $2.92 with a market cap of $109.8M.

What sector is Genelux Corporation in?

Genelux Corporation (GNLX) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is GNLX a good stock to buy?

Analysts have a Buy consensus on GNLX with a price target of $17.33. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

GNLX Genelux Corporation

Healthcare

$2.92+0.00%ClosedMarket Cap: $109.8M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

4.14

P/S

13730.17

EV/EBITDA

-3.10

DCF Value

$0.10

FCF Yield

-25.4%

Div Yield

0.0%

Margins & Returns

Gross Margin

-3550.0%

Operating Margin

-422037.5%

Net Margin

-397225.0%

ROE

-165.2%

ROA

-98.2%

ROIC

-132.8%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-7.1M	$—
Q4 null	$8.0K	$-9.2M	$—
FY null	$8.0K	$-32.1M	$—
Q3 null	$0.00	$-8.0M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$17.33

Target (Median)

$16.00

Target Range

$16.00 - $20.00

1 Strong Buy5 Buy0 Hold0 Sell0 Strong Sell

BenchmarkSpeculative Buy

2026-03-20

Trading Activity

Insider Trades

View All

Zindrick Thomasofficer: President and CEO

SellTue May 12

Yu Yongofficer: Chief Scientific Officer

SellTue May 12

Smalling Ralphofficer: Head of Regulatory

SellTue May 12

Cappello Josephofficer: Chief Technical Officer

SellTue May 12

Zindrick Thomasofficer: President and CEO

SellThu Mar 26

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.50

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

Peers